Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a 'Buy' rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $66 to $74.
October 27, 2023 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst maintains a 'Buy' rating on Blueprint Medicines and raises the price target from $66 to $74, indicating positive sentiment towards the stock.
The raised price target by Needham analyst indicates a positive outlook for Blueprint Medicines. This could potentially lead to an increase in the stock price in the short term as it signals the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100